Clinical Trials

To assess the effectiveness of daily TransCon PTH on serum and calcium levels and active vitamin D and calcium doses at 4 weeks of treatment.

This trial has a duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.

During the first 26 weeks of the trial, participants will be randomly assigned to one of two groups: one group will receive TransCon PTH and one group will receive placebo. All subjects will start with a fixed dose of study drug and will be individually and progressively titrated to an optimal dose over a 10 week period, followed by an individualized dosing period up to 16 weeks. TransCon PTH or placebo will be administered as a subcutaneous injection using a pre-filled injection pen. Neither trial participants nor their doctors will know who has been assigned to each group. After the ...

Will teriparatide ( Forteo) shorten the length of hospitalization post thyroidectomy in patients with symptomatic hypoparathyroidism

The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).

This study is being conducted to characterize the effects of twice daily administration of rhPTH(1-84) on the way the body handles rhPTH(1-84) as well as its actions and safety and tolerability over the course of 24 hours as compared with the current once daily dosing regimen of marketed rhPTH(1-84) (marketed in the United States as Natpara®).

The purpose of this study is to collect patient samples to Ortho Clinical Diagnostics for evaluation of an in-development VITROS Intact PTH II assay and the characterization of different clinical cohorts on this immunoassay.  The categories include those for primary hyperparathyroidism, including routine samples and those intraoperative samples obtained during the course of a parathyroidectomy procedure, secondary hyperparathyroidism, including routine and intraoperative samples from patients with kidney failure tertiary hyperparathyroidism, primary hypoparathyroidism, and hypercalcemia of malignancy.